" class="no-js "lang="en-US"> Liminatus Pharma - Medtech Alert
Tuesday, October 01, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Liminatus Pharma | PTF

Liminatus Pharma

About Liminatus Pharma

Liminatus Pharma

Liminatus is a clinical-stage biopharmaceutical company developing novel cancer therapies that exploit the body’s immune system to recognise and attack cancer cells. The development pipeline consists of chimeric antigen receptor (CAR)-T cell therapeutics, Guanylyl Cyclase C (GCC) cancer vaccine and CD47 immune checkpoint inhibitor.

Related Story

Clinical Trials

 Liminatus Pharma and Iris Acquisition Corp to Combine to Incorporate and Accelerate Much-needed Cancer Treatments | PTF

Liminatus Pharma and Iris Acquisition Corp to Combine to Incorporate and Accelerate Much-needed Cancer Treatments

December 1 2022

Liminatus Pharma LLC, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition […]